CSF3 and small cell lung carcinoma: However, in our case series analysis of selected advanced SCLC patients included in a prospective pharmacokinetic trial, the rate of neutropenic complications in patients not receiving primary G-CSF prophylaxis was substantially high, already in the first cycle.